---
document_datetime: 2025-07-08 16:09:16
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qdenga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: qdenga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3720174
conversion_datetime: 2025-12-25 00:11:07.113042
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Qdenga

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11034 /202408  | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / | 27/03/2025                          | 02/06/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11034/202408. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | virus, serotype 2, expressing Dengue virus, 4, surface proteins, live, attenuated / virus, serotype 2, live, attenuated.]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | Dengue serotype Dengue   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------|
| WS/2777/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling 10-fold | 16/01/2025 | n/a | down to                  |
| WS/2742/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/10/2024 | n/a |                          |

<div style=\"page-break-after: always\"></div>

|                     | 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS   |            |            |             |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| WS/2695             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                     | 31/10/2024 | 02/06/2025 | SmPC and PL |                                   |
| WS/2750             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                   | 03/10/2024 | 02/06/2025 | SmPC        |                                   |
| PSUSA/11034 /202402 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Dengue virus, serotype 2, expressing Dengue virus,                                                                                                                                                                                                                                                                                                     | 03/10/2024 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

|                     | serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated / Dengue virus, serotype 2, live, attenuated.]                                                                                                                                                 |            |            |             |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2593             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                       | 05/09/2024 |            | SmPC and PL | For more information, please refer to the Summary of Product Characteristics.                                                              |
| IG/1766             | B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR                                                                                                                                                                                                                                                                                | 01/08/2024 | n/a        |             |                                                                                                                                            |
| PSUSA/11034 /202308 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated / Dengue virus, serotype 2, live, attenuated.] | 21/03/2024 | 17/05/2024 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11034/202308. |
| WS/2618             | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                  | 18/04/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | Commission Regulation (EC) No 1234/2008. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                         |            |     |               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------|
| WS/2575   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                                                                                                                           | 14/12/2023 | n/a | biological AS |
| IG/1669/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 25/10/2023 | n/a |               |

<div style=\"page-break-after: always\"></div>

| WS/2522/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | 19/10/2023   | n/a   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/11034 /202302 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated / Dengue virus, serotype 2, live, attenuated.]                                                                                                                                                                   | 28/09/2023   | n/a   | PRAC Recommendation - maintenance |
| IB/0009             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                            | 09/08/2023   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0006   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/07/2023   | n/a   |                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------|
| IB/0005/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                                                                                                                        | 23/06/2023   | n/a   | duplication of line) |
| IB/0003   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/04/2023   | n/a   |                      |
| IB/0002/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other | 12/04/2023   | n/a   |                      |

<div style=\"page-break-after: always\"></div>

|           | or addition) for the AS or a starting material/intermediate B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001/G | This was an application for a group of variations.                                                                                                                             | 15/03/2023 | n/a |